Bacteriophage Pretreatment Composition for MRSA Drug Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing diversification of methicillin-resistant Staphylococcus aureus (MRSA) infections, including community-acquired and livestock-associated strains, necessitates the development of individualized therapeutic strategies that enhance drug sensitivity to antibacterial drugs and reduce virulence.
Innovation Solution
A composition containing specific bacteriophages, identified by accession numbers NITE BP-693 and NITE BP-694, is used to increase MRSA's resistance to these drugs, thereby enhancing drug sensitivity and reducing virulence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bacteriophages are used to treat MRSA infections, then drug sensitivity is increased, but the bacteria develop resistance to the bacteriophages
Solution Approach 1:
The patent applies preliminary action by pre-treating MRSA with bacteriophages before administering antibacterial drugs. This sequence allows the bacteriophages to temporarily infect and sensitize the bacteria, making them more vulnerable to subsequent antibacterial drug treatment, thereby achieving enhanced drug sensitivity without permanent bacteriophage resistance development
2Reliability
If bacteriophages are applied to increase drug sensitivity, then therapeutic effect is enhanced, but the complexity of treatment protocol increases
Solution Approach 1:
The patent merges the bacteriophage treatment and antibacterial drug treatment into a unified therapeutic protocol. By combining these two approaches in a coordinated sequence, the treatment achieves enhanced therapeutic effect while maintaining protocol manageability through integrated administration strategies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively increases MRSA's sensitivity to antibacterial drugs, such as β-lactams, and reduces virulence by allowing MRSA to acquire resistance to the bacteriophages, providing therapeutic and preventive benefits against MRSA infections.
Implementation Method 1
bacteriophages, a collective term for viruses that infect bacteria, infect bacteria as a host and then grow in the bacteria. Daughter phages resulting from the growth are discharged out of the bacterial cells through the cell walls of the bacteria, and the bacteria undergo bacteriolysis to die.
Data Source
AI summary
This composition for improving the drug sensitivity of an antibacterial drug to methicillin-resistant Staphylococcus aureus (MRSA) comprises at least one bacteriophage selected from the group consisting of the bacteriophage identified by accession number NITE BP-693 and the bacteriophage identified by accession number NITE BP-694.